Business Context and Reporting Period
This Form 8-K Current Report from Supernus Pharmaceuticals, Inc. covers events occurring on March 30, 2023, with the report dated April 3, 2023. The filing primarily addresses a significant debt refinancing transaction involving the repayment of maturing convertible notes.
Key Financial Metrics and Debt Activity
- New Borrowing: On March 30, 2023, the Company borrowed $93 million under a revolving credit line agreement with UBS Bank USA.
- Debt Repayment: The proceeds from the new borrowing, combined with available cash, were used to pay in full the Company's 0.625% Convertible Senior Notes due April 1, 2023.
- Credit Facility Terms: The UBS Credit Line provides up to $150 million for general corporate purposes. Borrowings accrue interest at a variable rate (UBS Variable Rate plus an applicable spread).
- Collateral: The Credit Line is secured by a first-priority lien on the Company's cash, marketable securities, and other investment assets held in accounts with UBS.
- Liquidity and Cash Flow: The filing does not provide specific total cash balance, operating cash flow, or revenue figures for the period.
Material Changes Versus Prior Period
The primary material change is the elimination of the Convertible Senior Notes liability and the simultaneous incurrence of $93 million in variable-rate debt. This transaction alters the Company's capital structure by replacing fixed-rate convertible debt with a secured revolving credit facility.
Outlook, Risks, and Contingencies
- Collateral Maintenance: The Company may be required to post additional collateral if the value of the pledged assets declines below required maintenance levels.
- Lender Discretion: UBS retains the right to demand full or partial repayment of the Credit Line and terminate the agreement at any time without cause.
- Default Provisions: Upon customary events of default, all amounts under the Credit Line become immediately due, and UBS has the right to liquidate collateral.
- Management Commentary: The filing states the Credit Line agreement is not intended to provide factual information about the Company's actual conduct of business beyond the terms of the agreement.
Key Facts for Investor Verification
- Verify the total outstanding balance on the UBS Credit Line following the $93 million draw.
- Confirm the current value of the Company's collateral assets held at UBS to assess the risk of additional collateral calls.
- Review the specific "applicable Percentage Spread" and "UBS Variable Rate" to determine the current effective interest cost.
- Check subsequent filings for any additional draws on the $150 million facility or changes in the Company's liquidity position.